The number of NSCLC patients above 70 years of age who are non-squamous histology is
increasing around the world. Although previous guidelines often recommend single agent
therapy for NSCLC, recent studies suggest that platinum doublets may be better than standard
monotherapy in elderly. We hypothesize that for elder patients (≥70 years of age) with
non-squamous NSCLC, pemetrexed and carboplatin is more effective than pemetrexed monotherapy
in terms disease progression, overall survival, and quality of life and tolerability.